Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $19,478 - $29,064
10,198 New
10,198 $24,000
Q1 2021

May 13, 2021

SELL
$3.14 - $4.84 $112,490 - $173,393
-35,825 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$2.76 - $4.97 $98,876 - $178,050
35,825 New
35,825 $127,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $489M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Alpine Global Management, LLC Portfolio

Follow Alpine Global Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpine Global Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpine Global Management, LLC with notifications on news.